Company Overview and News

Fitch affirms Sri Lanka’s Abans at BBB+(lka); outlook stable

2017-09-26 lankabusinessonline
Fitch Ratings has affirmed Sri Lanka-based retailer Abans PLC’s (Abans) National Long-Term Rating at ‘BBB+(lka)’ with a Stable outlook. Fitch has also withdrawn the expected rating assigned to Abans’ proposed senior unsecured debentures as the debt issuance is no longer expected to convert to final ratings in the near future. A full list of rating actions is at the end of this commentary.

TVS ties up with Abans Auto to launch 3-wheeler in Sri Lanka

2017-06-28 thehindubusinessline
Chennai-based TVS Motor Company today announced a partnership with Abans Auto, a leading distributor in Sri Lanka, to launch its 200 cc passenger three-wheeler TVS King in the island nation.

TVS ties up with Abans Auto to launch 3-wheeler in Sri Lanka

2017-06-28 moneycontrol
Chennai-based TVS Motor Company today announced a partnership with Abans Auto, a leading distributor in Sri Lanka, to launch its 200 cc passenger three-wheeler TVS King in the island nation.

Sri Lanka’s Abans Finance to raise capital with Rs277mn rights issue

2016-12-28 lankabusinessonline
Dec 28, 2016 (LBO) – Sri Lanka’s finance sector player, Abans Finance, is to raise 277.34 million rupees by way of a rights issue, the company said in a stock exchange filing.

Fitch assigns Abans’s proposed debenture BBB+(lka)(EXP)

2016-10-21 lankabusinessonline
Fitch Ratings has assigned Abans PLC’s (Abans; BBB+(lka)/Stable) proposed senior unsecured debenture issue of up to LKR1.5bn a National Long-Term Rating of ‘BBB+(lka)(EXP)’.

Abans engages MTI for competitive edge in HRM

The Abans Group, operating across multiple sectors in Sri Lanka, has concluded another advisory assignment with MTI Consulting, this time focusing on Human Resource and Talent Optimization. The Abans Group is also one of the Investment Pledgers and Sponsors of MTI’s ‘idea2fund’ which is also proving to be a source of entrepreneurial talent for the highly diversified and fast growing group.

Abans Finance to raise Rs277mn through private placement

2016-06-27 lankabusinessonline
June 27, 2016 (LBO) – The directors of Abans Finance has decided to raise 277 million rupees for the company by way of a private placement of ordinary voting shares.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

21h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...